Powered by 
Technavio
Synta Pharmaceuticals | Data-Driven Analysis and Industry Review
Published: August 20, 2024Synta Pharmaceuticals Corporation was a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions. The company's lead product candidate, elesclomol, was an investigational oral small molecule designed to reactivate tumor suppressor proteins and restore their normal function in cancer cells. Synta Pharmaceuticals was headquartered in Lexington, Massachusetts, and had additional facilities in Europe and India. The company's mission was to develop new medicines that address some of the most important causes of disease and suffering, with a focus on oncology and aging. Synta Pharmaceuticals was acquired by Madrigal Pharmaceuticals in 2019.'
1. Focus on developing novel therapies for cancer and fibrotic diseases: Synta Pharmaceuticals specializes in creating innovative treatments for diseases with high unmet medical needs, specifically in the areas of cancer and fibrosis.
2. Collaborative partnerships: The company has formed strategic collaborations with various organizations, including the National Cancer Institute and the European Organisation for the Research and Treatment of Cancer, to expand its research capabilities and accelerate the development of its pipeline.
3. Clinical-stage pipeline: Synta Pharmaceuticals boasts a robust clinical-stage pipeline, with multiple candidates in various stages of development for various indications, such as STA-12-106 for the treatment of acute myeloid leukemia and STA-4783 for the treatment of systemic sclerosis.
4. Commercial-stage product: Synta Pharmaceuticals has one commercial-stage product, Elanva (elafibranor), which is approved in Europe for the treatment of non-alcoholic steatohepatitis (NASH) and is under review by the US Food and Drug Administration (FDA).
5. Global presence: The company has a strong global presence, with operations in the United States, Europe, and Asia, enabling it to collaborate with leading researchers and healthcare providers to bring its therapies to patients around the world.
1. Synta Pharmaceuticals' Business Intelligence (BI) team utilizes data analytics and reporting tools to transform raw data into meaningful insights, enabling informed decision-making for the company's leadership and departments.
2. The BI team at Synta Pharmaceuticals employs advanced data visualization techniques to present complex data in an easily understandable format, facilitating effective communication of key performance indicators (KPIs) and trends.
3. Synta Pharmaceuticals' BI team leverages both internal and external data sources to gain a comprehensive understanding of the company's performance and market landscape, enabling data-driven strategic planning and tactical actions.
4. The team also implements and maintains BI solutions, such as data warehouses and business intelligence software, ensuring data accuracy, security, and accessibility for authorized users.
5. Synta Pharmaceuticals' BI team collaborates closely with various business units and functions, such as sales, marketing, and research and development, to align data analysis efforts with the organization's strategic objectives and priorities.
Browse Our Research Portfolio In Synta Pharmaceuticals Markets
Health Care
Health Care
Health Care
Pharmaceuticals
Pharmaceuticals
Pharmaceuticals
Pharmaceuticals
Pharmaceuticals
Pharmaceuticals
About Technavio
With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.
